In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma

Cancer origin and development is associated not only with genetic alterations, but also with the disturbance of epigenetic profiles.1 In this regard, the tumoral epigenome is characterized by both specific and general shifts in the DNA methylation and histone-modification landscapes.1 However, in contrast to genetic disruption, the effect of epigenetic modifications or marks may potentially be reversed by the use of drugs that target enzymes involved in adding, removing or signaling DNA methylation and histone modifications.1 This basic knowledge has been adopted into clinical practice, and inhibitors of histone deacetylases and DNA demethylating agents have been approved for use in the therapy of hematologic malignancies, such as cutaneous T-cell lymphoma and myelodysplastic syndrome, respectively.2 Other promising epigenetic drugs include inhibitors of histone methyltransferases,2 histone demethylases,2 histone kinases,3 and bromodomain proteins that interfere with the 'reading' of acetylated histone residues

Ultrasmall manganese ferrites for in vivo catalase mimicking activity and multimodal bioimaging

Manganese ferrite nanoparticles display interesting features in bioimaging and catalytic therapies. They have been recently used in theranostics as contrast agents in magnetic resonance imaging (MRI), and as catalase-mimicking nanozymes for hypoxia alleviation. These promising applications encourage the development of novel synthetic procedures to enhance the bioimaging and catalytic properties of these nanomaterials simultaneously. Herein, a cost-efficient synthetic microwave method is developed to manufacture ultrasmall manganese ferrite nanoparticles as advanced multimodal contrast agents in MRI and positron emission tomography (PET), and improved nanozymes. Such a synthetic method allows doping ferrites with Mn in a wide stoichiometric range (MnxFe3-xO4, 0.1 ≤ x ≤ 2.4), affording a library of nanoparticles with different magnetic relaxivities and catalytic properties. These tuned magnetic properties give rise to either positive or dual-mode MRI contrast agents. On the other hand, higher levels of Mn doping enhance the catalytic efficiency of the resulting nanozymes. Finally, through their intracellular catalase-mimicking activity, these ultrasmall manganese ferrite nanoparticles induce an unprecedented tumor growth inhibition in a breast cancer murine model. All of these results show the robust characteristics of these nanoparticles for nanobiotechnological applications.The authors thank M. Jeannin from Lasie Laboratory (La Rochelle University) for the Raman studies. S.C.R. is supported by the grant PID2019-106139RA-100 funded by MCIN. J.R.-C. is supported by grants from the Ministerio de Economía, Industria y Competitividad (MEIC) (SAF2017-84494-C2-R). J.R.C. received funding from the BBVA Foundation (PR [18]_BIO_IMG_0008) and La Caixa (HR18-00052). Y.F.-A. received funding from the Santander-Universidad Zaragoza Fellowship program. L.G. acknowledges financial support from the Ramón y Cajal program (RYC-2014-15512). CIC biomaGUNE is supported by the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (MDM-2017-0720). The authors acknowledge the use of Servicio General de Apoyo a la Investigación-SAI, Universidad de Zaragoza. H.G. is supported by the Ligue contre le Cancer (CD16, CD17) and Région Nouvelle Aquitaine (Projet “Nanovect”). J.A.E. is supported by RTI2018-099357-B-I00, HFSP (RGP0016/2018), CIBERFES16/10/00282 and RED2018-102576-T. The CNIC is supported by the Pro-CNIC Foundation and by the Severo Ochoa of Excellence Program.Peer reviewe

Mind the Gap! Tailoring Sol-gel Ceramic Mesoporous Coatings on Labile Metal-organic Frameworks through Kinetic Control.

Surface engineering of metal-organic frameworks (MOFs) with a mesoporous silica coating can improve MOF mechanical properties and provide an easy way to decorate MOF nanoparticles with organic or biological molecules though silane chemistry or electrostatic interactions, while retaining open access to MOF porosity. Silica coating would be highly beneficial for employing MOFs in a wide range of applications such as catalysis or drug delivery. However, obtaining a stable, controlled core-shell structure using MOF nanoparticles as seed is challenging because of their intrinsic chemically labile nature. Here we analyze the factors that destabilize the core of the Zeolitic Imidazolate Framework-8 (ZIF-8) MOFs during the sol-gel deposition of a mesoporous silica shell causing a partial or total etching of the MOF material. Silicates in solution are found to scavenge Zn2+ ions removing them from the ZIF structure and causing a partial or complete dissolution of the ZIF seed. By carefully tuning the silicate concentration in solution simultaneous control can be obtained over both the ZIF-8 dissolution and the silica condensation kinetics, resulting in the growth of a uniform mesoporous silica shell while preserving the integrity of ZIF-8. The core-shell nanoparticles obtained show a compact core shell structure with no gap between the MOF core and the silica shell, even after calcination, while the crystalline ZIF-8 structure is retained. Overall, a general synthetic approach is presented for producing nanocomposite core-shell materials which can be applied to other MOF labile seed to design new hierarchical materials

Rational Design and Experimental Analysis of Short-Oligonucleotide Substrate Specificity for Targeting Bacterial Nucleases

An undecamer oligonucleotide probe based on a pair of deoxythymidines flanked by several modified nucleotides is a specific and highly efficient biosensor for micrococcal nuclease (MNase), an endonuclease produced by Staphylococcus aureus. Herein, the interaction mode and cleavage process on such oligonucleotide probes are identified and described for the first time. Also, we designed truncated pentamer probes as the minimum-length substrates required for specific and efficient biosensing. By means of computational (virtual docking) and experimental (ultra-performance liquid chromatography-mass spectrometry and matrix-assisted laser desorption ionization time-of-flight) techniques, we perform a sequence/structure-activity relationship analysis, propose a catalytically active substrate-enzyme complex, and elucidate a novel two-step phosphodiester bond hydrolysis mechanism, identifying the cleavage sites and detecting and quantifying the resulting probe fragments. Our results unravel a picture of both the enzyme-biosensor complex and a two-step cleavage/biosensing mechanism, key to the rational oligonucleotide design process.Funding Agencies|Wallenberg Centre for Molecular Medicine (WCMM) Linkoping, Sweden; Swedish Government Strategic Research Area in Materials Science on Advanced Functional Materials at Linkoping University (Faculty grant SFO-Mat-LiU) [2009-00971]; Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency [MDM-2017-0720]; industrial doctorate program (MINECO) [DI-16-08891]; program Torres Quevedo (MINECO) [PTQ-17-09382]</p

Ultrasmall Manganese Ferrites as Multimodal Bioimaging Agents and Fenton/Haber-Weiss Catalysts

Ultrasmall manganese ferrite nanoparticles display interesting features in bioimaging and Fenton nanocatalysis. However, little is known about how to optimize these nanoparticles to achieve simultaneously the highest efficiency in both types of applications. Herein, we present a cost-efficient synthetic microwave method that enables manganese ferrite nanoparticles to be produced with excellent control in size, chemical composition and colloidal stability. We show how the reaction’s pH has a substantial impact on the Mn incorporation into the nanoparticles and the level of Mn doping can be finely tailored to a wide range (MnxFe3-xO4, 0.1 ≤ x ≤ 2.4). The magnetic relaxivities (1.6 ≤ r1 ≤ 10.6 mM-1s-1 and (7.5 ≤ r2 ≤ 29.9 mM-1s-1) and Fenton/Haber-Weiss catalytic properties measured for the differently doped nanoparticles show a strong dependence on the Mn content and, interestingly, on the synthetic reaction’s pH. Positive contrast in magnetic resonance imaging is favored by low Mn contents, while dual mode magnetic resonance imaging contrast and catalytic activity increases in nanoparticles with a high degree of Mn doping. We show that this is valid in solution, in a murine model and intracellularly respectively. Besides, this synthetic protocol allows core-radiolabeling for high-sensitive molecular imaging while maintaining relaxometric and catalytic properties. All of these results show the robust characteristics of these multifunctional manganese ferrite nanoparticles as theranostic agents.</p

In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma

Cancer origin and development is associated not only with genetic alterations, but also with the disturbance of epigenetic profiles.1 In this regard, the tumoral epigenome is characterized by both specific and general shifts in the DNA methylation and histone-modification landscapes.1 However, in contrast to genetic disruption, the effect of epigenetic modifications or marks may potentially be reversed by the use of drugs that target enzymes involved in adding, removing or signaling DNA methylation and histone modifications.1 This basic knowledge has been adopted into clinical practice, and inhibitors of histone deacetylases and DNA demethylating agents have been approved for use in the therapy of hematologic malignancies, such as cutaneous T-cell lymphoma and myelodysplastic syndrome, respectively.2 Other promising epigenetic drugs include inhibitors of histone methyltransferases,2 histone demethylases,2 histone kinases,3 and bromodomain proteins that interfere with the 'reading' of acetylated histone residues

In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma

Cancer origin and development is associated not only with genetic alterations, but also with the disturbance of epigenetic profiles.1 In this regard, the tumoral epigenome is characterized by both specific and general shifts in the DNA methylation and histone-modification landscapes.1 However, in contrast to genetic disruption, the effect of epigenetic modifications or marks may potentially be reversed by the use of drugs that target enzymes involved in adding, removing or signaling DNA methylation and histone modifications.1 This basic knowledge has been adopted into clinical practice, and inhibitors of histone deacetylases and DNA demethylating agents have been approved for use in the therapy of hematologic malignancies, such as cutaneous T-cell lymphoma and myelodysplastic syndrome, respectively.2 Other promising epigenetic drugs include inhibitors of histone methyltransferases,2 histone demethylases,2 histone kinases,3 and bromodomain proteins that interfere with the 'reading' of acetylated histone residues